Feb 11, 2006|
Life after 10k...
While it was merry making time for the bulls on Dalal Street, the bears were left licking their wounds after their big defeat, as the bulls cruised into the 10,000+ territory with surprising ease this week. The Indian stockmarkets created history yet again this week, as the Sensex breached the 10,000 mark with its near-4% gains. The Nifty too gained 3% and is now comfortably perched in the 3,000+ zone. With the largely decent 3QFY06 results out of the way, a scenario wherein global markets are flush with liquidity and the Indian Budget is round the corner, which has resulted in some expectations build-up amongst market participants, has led to the optimistic behaviour on the bourses.
Despite last week's correction that saw the Sensex lose almost 180 points in the second half of the trading week, markets opened on Monday on an optimistic note. They traded rock solid for the entire trading session on Monday and by close, logged in one of the steepest single-day rises in recent history of the Indian stockmarkets (Sensex up 238 points). Thus, they not only covered the losses of the previous few trading sessions, but also managed to contribute further gains. However, more than this, Monday's trading session (February 6, 2006) will be remembered for the historic event of the Sensex breaching the much-awaited 10,000-mark!
Going into Tuesday's trade, while apprehensions abounded about the sustainability of these gains and levels, the Sensex rallied a further 100 points, leaving the bear camp struck in awe of the ferocious moves made by the bulls. However, Wednesday's trading session saw some profit booking at higher levels, leading to a marginal correction, before buying resumed on Friday (Thursday being a holiday) and the BSE-Sensex continued its record run, registering new lifetime highs. Further, the buying action was not restricted to large caps alone. The mid-cap and small-cap stocks also witnessed investor interest, albeit at a relatively cautious pace. This was evident from the fact that while the Sensex closed higher by about 4%, the BSE Mid-cap Index and BSE Small-cap Index logged in gains of about 2.2% and 2.6% respectively.
As far as the institutional action this week was concerned, while Foreign Institutional Investors (FIIs), flushed with liquidity, continued to pump in huge amounts of money into Indian equities (see chart above), domestic mutual funds (MFs) preferred to remain net sellers. For the first 4 trading sessions of the week for which data is available, while FIIs bought over Rs 16 bn, MFs sold equities worth almost Rs 2 bn. Thus, with this, while FIIs have already invested around Rs 63 bn (almost US$ 1.5 bn) in 2006 to date, MFs have been net sellers of equities to the tune of Rs 20 bn (approx. US$ 450 m).
Top gainers over the week (NSE-50)
Feb 3 (Rs)
Feb 10 (Rs)
|| 10,122 / 6,118
|S&P CNX NIFTY
|| 3,032 / 1,896
|| 581 / 212
|| 568 / 339
|| 209 / 126
|| 927 / 471
|| 206 / 128
Now let us consider some sector/stock specific developments this week:
Cipla once again made it to the top gainers' list this week (up 16%), making it 25% gains in a mere 2 weeks! What continued to keep the stock in the limelight, as mentioned last week also, was the announcement made by the company regarding its plans for a bonus issue. The company's board of directors is scheduled to meet on February 11, 2006 to discuss this issue. It is also planning to consider the issue of raising funds and increasing the investment limit of foreign institutional investors (FIIs) in the company. Other pharma stocks
Domestic pharma major, Ranbaxy, was in the top gainers' list amongst the Nifty stocks this week. There were a couple of news items that could have helped work sentiments towards the stock. One, Ranbaxy has entered into a 70:30 JV with South-African based Community Investment Holdings (CIH), which will sell the former's range of anti-retroviral (ARV) products in South Africa and other African markets. The value of the African market is estimated to be between US$ 5 bn and US$ 8 bn and the market for ARVs is pegged at US$ 70 m to US$ 100 m. While realisations are likely to be lower, higher volumes are expected to drive growth. In another news, the company has reportedly bid 500 m euros (around Rs 28 bn) for Betapharm, which is Germany's fourth-largest generic company. Both these moves are part of Ranbaxy's strategy to expand its geographical reach. Other pharma stocks
Two-wheeler auto stocks found favour amongst participants this week. This was seemingly the fallout of a good set of volume numbers reported by leading two-wheeler companies for the month of January 2006. For January 2006, while Bajaj Auto (up 3%) continued to outperform the industry growth with a 28% YoY growth in its volumes, TVS Motor (down marginally) reported a strong 20% YoY growth led by its motorcycle sales, which grew by 25% YoY. However, Hero Honda (up 9%) registered a single digit growth. It should be noted that the strong growth numbers in January 2006 should be viewed in the backdrop of the subdued performance in the months of November and December 2005. Other auto stocksTop losers over the week (NSE-50)
Feb 3 (Rs)
Feb 10 (Rs)
|| 297 / 199
|| 456 / 329
|| 380 / 282
|| 395 / 193
|| 548 / 272
Following the footsteps of the largest housing finance company in the country, HDFC (up 4%), the other two market leaders in this segment of financing, ICICI Bank (up 6%) and SBI (up 3%), have also indicated a 50 basis points rise in interest rates. Hardening of interest costs have now started pressurising the net interest margins of banks to unsustainable levels, which is necessitating this move. The bankers are of the view that while the current round of interest rate hikes will not affect the incremental demand for credit, the continuation of the current trend of hardening rates over a longer period of time would act as a dampener. Also, the rate hike is expected to reflect in auto loans in the medium term, while the high-yielding personal loans and credit cards are likely to remain shielded. Other banking stocks
So, what's in store for an investor beyond 10,000? While this continues to remain the billion-dollar question, with only 'guesstimates' (guessed estimates) as the probable answers, there are a few points that investors must bear in mind. While there is no denying the fact that India Inc.'s performance has been nothing less than splendid, there have been noticeable signs of a slowdown in corporate profit growth in 3QFY06. Further, with the capex cycle on the upturn, corporates would have to bear additional costs on their debt with interest rates on the rise, which would suppress profitability growth.
Moreover, the Indian stockmarkets now are not only more expensive (Sensex P/E of 18.6 times trailing 12-months earnings) than what they were a year ago (15.6x), they are also relatively expensive compared to other Asian markets (Hong Kong – 14x, Korea - 11x, Thailand – 10x), despite considering India's growth potential. This warrants caution as, in the event of FII money flowing back with US interest rates now well above 4% compared to 1% in June 2004, there is the possibility of a larger share being pulled out from India.
While we should not be construed as belonging to the bear camp, we continue to believe that at the current juncture, it would be wise to look at the downside first rather than the upside. Further, we continue to advocate investing in fundamentally sound companies with a 3 to 5 year view, as we remain positive on India as a growth story and equities as an asset class in the long-term. Happy and safe investing!
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407